Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 6, 2026Antibody TherapeuticsOpen Access

Subcutaneous Administration of Antibody–Drug Conjugates: Current Challenges, Emerging Opportunities, and Future Perspectives

View Full Paper
Ask AI
Bookmark
Share

Authors

SRSteven RenSWShawn Shouye WangFLFrank Yunsong Li

Discussion

Loading...

Member takes

Overview

This review evaluates the feasibility of subcutaneous antibody-drug conjugates, highlighting potential benefits and challenges for clinical use.

Key Points

  • The aim is to assess the feasibility and implications of subcutaneously administering antibody-drug conjugates (ADCs).
  • Review of pharmacokinetic and pharmacodynamic studies related to ADCs
  • Evaluation of clinical data and emerging molecular design technologies
  • Discussion on enabling strategies for SC delivery such as polymer-based systems
  • Antibody-drug conjugates show potential for subcutaneous delivery but face unique challenges such as linker instability and injection-site reactions.
  • Successful SC administration is highly dependent on the specific molecular properties and formulation of the ADCs.
  • Recent examples like JSKN033 demonstrate promising high-concentration formulations for SC delivery.

Cite This Study

Ren et al. (2026) studied this question.

synapsesocial.com/papers/6a23bc2a71a5da9775e779b9https://doi.org/10.1093/abt/tbag028
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Antibody–drug conjugates in cancer therapy: current landscape, challenges, and future directions2025 · 88 citations
  2. 2Advancing Antibody-Drug Conjugates: Current Perspectives and Future Directions2026 · 1 citations
  3. 3Strategic and Chemical Advances in Antibody–Drug Conjugates2025 · 33 citations
  4. 4Antibody–Drug Conjugates: Pharmacotherapeutic Properties and Future Perspectives2026 · 1 citations
  5. 5Advances and Future Directions in Antibody–Drug Conjugates: From Paradigm Shifts to Data-Driven Design2026